Evidence map›Paper›PMID 26058862›Full record

ArticleAmerican journal of physiology. Endocrinology and metabolism2015

Dual actions of a novel bifunctional compound to lower glucose in mice with diet-induced insulin resistance.

Katherine Chen, Alice Jih, Sarah T Kavaler, William S Lagakos, Dayoung Oh, Steven M Watkins, Jane J Kim

Erratum issuedAbstract readComparative Study
PubMed Full text at PMC Publisher
In one paragraph

Article in American journal of physiology. Endocrinology and metabolism, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. An erratum has been issued. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
0.4field-weighted citation impact, top 31% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed, 2 citations in OpenAlex.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

5 · Who and what money

Authors and funding

7 authors at 2 institutions in 1 country.

Katherine ChenDepartment of Pediatrics, University of California at San Diego, La Jolla, California;
Alice JihDepartment of Pediatrics, University of California at San Diego, La Jolla, California;
Sarah T KavalerDepartment of Pediatrics, University of California at San Diego, La Jolla, California;
William S LagakosDepartment of Medicine, University of California at San Diego, La Jolla, California;
Dayoung OhDepartment of Medicine, University of California at San Diego, La Jolla, California;
Steven M WatkinsMetabolon, Durham, North Carolina; and.
Jane J KimDepartment of Pediatrics, University of California at San Diego, La Jolla, California; Rady Children's Hospital of San Diego, San Diego, California janekim@ucsd.edu.
University of California, San Diego · USMetabolon (United States) · US

Funding

Transgenic & Knock-out MouseP30DK063491 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI PETER J TONTONOZ · 2003 to 2026
$40.4M
Studies of Fox01 in Insulin Resistance and its interaction with PPARgammaK08DK075479 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KIM, JANE · 2007 to 2011
$681k
Epigenetics of Obesity and Insulin ResistanceR03DK097412 · NIDDK · UNIVERSITY OF CALIFORNIA, SAN DIEGO · PI KIM, JANE · 2013 to 2014
$155k
NIDDK NIH HHS DK-075479NIDDK NIH HHS DK-097412NIDDK NIH HHS P30 DK-063491NIDDK NIH HHS P30 DK063491
6 · The paper itself

Abstract

Docosahexaenoic acid (DHA 22:6n-3) and salicylate are both known to exert anti-inflammatory effects. This study investigated the effects of a novel bifunctional drug compound consisting of DHA and salicylate linked together by a small molecule that is stable in plasma but hydrolyzed in the cytoplasm. The components of the bifunctional compound acted synergistically to reduce inflammation mediated via nuclear factor κB in cultured macrophages. Notably, oral administration of the bifunctional compound acted in two distinct ways to mitigate hyperglycemia in high-fat diet-induced insulin resistance. In mice with diet-induced obesity, the compound lowered blood glucose by reducing hepatic insulin resistance. It also had an immediate glucose-lowering effect that was secondary to enhanced glucagon-like peptide-1 (GLP-1) secretion and abrogated by the administration of exendin(9-39), a GLP-1 receptor antagonist. These results suggest that the bifunctional compound could be an effective treatment for individuals with type 2 diabetes and insulin resistance. This strategy could also be employed in other disease conditions characterized by chronic inflammation.

Indexed as

Insulin ResistanceAdministration, OralAnimalsAnti-Inflammatory Agents, Non-SteroidalBlood GlucoseCell Line, TransformedCell Line, TumorCells, CulturedDiet, High-FatDocosahexaenoic AcidsGlucagon-Like Peptide 1HumansHypoglycemic AgentsLiverMacrophagesMice, Inbred C57BLAnti-Inflammatory Agents, Non-SteroidalBlood GlucoseDocosahexaenoic AcidsGlucagon-Like Peptide 1Hypoglycemic AgentsProdrugsSal-DHA compoundSalicylatesdocosahexaenoic acidinsulin-resistanceobesitysalicylate

Identifiers

PMID26058862
PMCPMC4525113
OpenAlexW2192914977

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.